Search Results

BioForest

Impel NeuroPharma to Participate in Upcoming Virtual Investor Conferences

Impel NeuroPharma announced that Adrian Adams, Chairman and Chief Executive Officer, will participate in the following upcoming investor conferences.

February 28, 2022

·

1 min read

BioForest

Impel NeuroPharma to Ring Nasdaq Closing Bell on Monday, April 25

Impel NeuroPharma announced that Chairman of the Board and Chief Executive Officer, Adrian Adams will ring the Nasdaq Stock Market closing bell on Monday, April 25, 2022.

April 21, 2022

·

6 min read

BioForest

Impel Neuropharma Announces $100 Million Royalty and Debt Financing Agreement With Oaktree

Impel NeuroPharma announced two separate transactions with funds managed by Oaktree Capital Management, L.P. totaling $100 million in gross funding.

March 17, 2022

·

5 min read

BioForest

Impel NeuroPharma Provides Updates on Trudhesa™ Launch and Recent Business Highlights

Impel NeuroPharma today provided updates on Trudhesa™ (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) launch progress and recent business highlights.

January 18, 2022

·

11 min read

BioForest

Impel NeuroPharma To Present At The 21st Annual Needham Healthcare Conference

Impel NeuroPharma announced that Adrian Adams, Chairman and Chief Executive Officer, will present a company overview at the 21st Annual Needham Healthcare Conference being held virtually on Thursday, April 14, 2022 at 1:30 p.m. ET.

April 7, 2022

·

1 min read

Genetown

PurMinds NeuroPharma Announces PUR501 as Lead Candidate Novel Non-Hallucinogenic Neuroplastogen

PurMinds NeuroPharma to initiate preclinical development of lead candidate PUR501 in 2024 in preparation for IND submission

May 30, 2024

·

4 min read

Business

PurMinds NeuroPharma Appoints Vanessa Williamson as Chief Business Officer

PurMinds NeuroPharma (“PurMinds™" or the “Company”), a clinical-stage neuroscience company focused on advancing a robust pipeline of small molecules, psychedelic compounds, and other modalities for the treatment of neurological and neurodegenerative disorders

May 23, 2024

·

3 min read

Business

Impel NeuroPharma Announces Second Quarter 2021 Financial Results and Provides Corporate Update

Impel NeuroPharma today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.

August 16, 2021

·

13 min read

BioForest

Impel NeuroPharma Launches Reroute Migraine Relief

Impel NeuroPharma (Nasdaq: IMPL), a late-stage biopharmaceutical company, today launched Reroute Migraine Relief , an educational initiative which aims to raise awareness of the complexities of migraine, including the underrecognized connection between the brain and gut.

May 18, 2021

·

8 min read

Business

Impel NeuroPharma to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 24, 2022

Impel NeuroPharma (NASDAQ: IMPL), today announced it will host a live webcast on Thursday, March 24, 2022, at 8:30 a.m. ET to report its fourth quarter and full year 2021 financial results and provide a business update.

March 17, 2022

·

1 min read